MD to Cap Out-of-Pocket Costs for Certain Prescription Drugs

Maryland’s Prescription Drug Affordability Board received approval to cap costs for certain prescription drugs under state and local health plans, reports AARP Maryland. The board will review six high-cost medications, including Ozempic and Dupixent, to determine affordability and potential savings. Caps will be imposed only if they lower costs without reducing access. The plan marks Maryland’s latest effort to rein in rising drug prices.